Author: Ravi Shankar

ATLANTA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Wisconsin-based transportation and logistics provider WEL Companies is using Descartes’ broker transportation management system (TMS) integrated with CARRIER1 Vault to move customers’ goods using its own trucks and to arrange shipments with other trucking companies in its for-hire network. The combined solution helps WEL’s freight brokers manage the shipment lifecycle with the Descartes solution while exchanging load information, status updates and delivery documents with the carriers and drivers moving the freight.

“The Descartes and CARRIER1 collaboration lets WEL automate communication and shipment data across our brokerage, our assets, and our for-hire carrier network, without our brokers ever leaving their TMS,” said Eric Lenze, EVP at WEL Companies. “That means a faster shipment lifecycle and a better experience for our customers.”

Descartes’ cloud-based broker TMS helps freight brokers and third-party logistics providers manage order entry, load coverage, carrier acceptance, dispatching and carrier communications. CARRIER1 Vault extends these workflows to trusted carriers and drivers through digital tendering, shipment tracking, communication and document exchange. As a load moves, carrier assignments, driver and equipment details, status updates and documents such as rate confirmations, bills of lading and proof of delivery can flow back to the corresponding load in the Descartes solution. The integration also supports carrier, driver and equipment verification, helping brokers reduce manual data entry and the need to piece together information from emails, spreadsheets and phone calls.

“Brokers need the systems that they already use to do more for them,” said Travis Rhyan, CEO of CARRIER1. “Connecting Vault with Descartes’ TMS brings the broker, carrier and driver into the same flow of information. The broker stays in their Descartes solution, the carrier gets what they need to move the load, and the information comes back without someone having to chase it down manually.”

“We’re pleased to help WEL Companies simplify brokerage operations by connecting more of the shipment lifecycle back into Descartes’ TMS through our integrated solution,” said Andrew Wimer, Associate General Manager at Descartes. “Our integration strategy gives brokers access to specialized capabilities while keeping Descartes’ TMS at the center of their operations. By collaborating with CARRIER1, we’re extending that approach to the carriers and drivers moving the freight, so brokers can spend less time gathering updates and documents and more time managing exceptions and serving customers.”

Learn more about Descartes’ transportation management solutions.

About WEL Companies

WEL Companies is a family-owned transportation, logistics and warehousing company headquartered in De Pere, Wisconsin. Founded in 1975, WEL provides refrigerated truckload and less-than-truckload transportation, integrated logistics and warehousing services. Learn more at www.welcompanies.com.

About CARRIER1

CARRIER1 connects freight brokers, carriers and drivers through technology designed to simplify the work surrounding a load. Its Vault platform integrates with existing transportation management systems to support carrier engagement, verification, shipment execution and document exchange. Learn more at www.carrier1.com.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack                                                                     
Tel: 226-750-8050                                 
cstrohack@descartes.com  

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ transportation management solution offerings and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

• BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancer
• The global Phase 3 ROSETTA Breast-01 trial will evolve to evaluate pumitamig in combination with sacituzumab govitecan, a TROP2-directed antibody-drug conjugate, reflecting the new standard of care in first-line treatment of metastatic triple-negative breast cancer
• This will be the first global Phase 3 trial of pumitamig in combination with an antibody-drug conjugate

MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy^®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb (“BMS”).

ROSETTA Breast-01 is a global, double-blinded Phase 3 clinical trial (NCT07173751) currently evaluating pumitamig in combination with chemotherapy versus chemotherapy in patients with locally advanced or metastatic PD-L1 low or negative TNBC (CPS < 10), initiated based on positive results from a global Phase 2 trial. In line with the evolving treatment landscape in this indication, BioNTech and BMS plan to adapt ROSETTA Breast-01 replacing chemotherapy with sacituzumab govitecan, pending regulatory authority approval, to ensure that patients are receiving the latest standard of care treatment.

Under the terms of the agreement, BioNTech will continue to sponsor and lead the ROSETTA Breast-01 trial. Gilead will supply sacituzumab govitecan for the combination trial.

“When the ROSETTA Breast-01 trial was initiated, chemotherapy was the only option for patients with PD‑L1 negative advanced TNBC. While chemotherapy remains a standard first-line option, TROP2-directed ADCs like sacituzumab govitecan are quickly becoming the new global standard of care. I am excited to evaluate the combination of pumitamig and sacituzumab govitecan in the ROSETTA Breast-01 trial to potentially further amplify the already meaningful improvement in patient outcomes that sacituzumab govitecan has demonstrated over chemotherapy,” said Peter Schmid, M.D., Ph.D., Lead Investigator and Director of the Breast Cancer Centre at St. Bartholomew’s Hospital.

Pumitamig is currently being investigated in seven ongoing global Phase 3 trials and 10+ Phase 2 novel-novel combination trials. ROSETTA Breast-01 will be the first global Phase 3 trial of pumitamig in combination with an ADC. BioNTech and Bristol Myers Squibb plan to evaluate the full potential of pumitamig in additional Phase 3 novel combination trials in multiple solid tumors, leveraging their broad oncology pipelines and exploring other potential additional collaborations.

“We aim to maximize potential benefit for patients with triple-negative breast cancer. Adapting ROSETTA Breast-01 to reflect the evolving standard of care gives the trial the best chance to inform clinical practice and, ultimately, treatment decisions for patients,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “Combining pumitamig as a potential backbone with complementary modalities such as ADCs is central to our therapeutic approach. Sacituzumab govitecan has advanced first‑line treatment of triple-negative breast cancer. By combining pumitamig and sacituzumab govitecan, we aim to determine whether this approach can further improve outcomes of patients.”

The use of pumitamig and sacituzumab govitecan in patients with first-line PD-L1 negative metastatic TNBC is investigational, and the safety and efficacy of this combination has not been established.

About Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which is defined by a lack of hormone receptors (estrogen or progesterone) and HER2 protein, accounts for about 10-15% of all invasive breast cancer cases.¹ It is an aggressive type of breast cancer that tends to grow and spread faster and has a worse prognosis compared to other breast cancer types. TNBC disproportionally impacts younger, premenopausal, and Black and Hispanic women. The 5-year survival rate for patients with metastatic TNBC is only 15%, emphasizing the need for new treatment options.¹

About Pumitamig
Pumitamig is an investigational bispecific immunomodulator, jointly developed by BioNTech and BMS, designed to cooperatively bind to PD-L1 and VEGF-A. It is aimed at restoring the immune system’s ability to recognize and destroy tumor cells while simultaneously cutting off the blood and oxygen supply that feeds tumor cells (anti-angiogenesis effect), preventing them from growing and proliferating. By anchoring to PD-L1 receptors on tumor cells, we believe pumitamig localizes VEGF-A blockade within the tumor microenvironment, potentially enhancing antitumor activity while minimizing systemic exposure.

More than 4,000 patients have been treated with pumitamig in clinical trials to date. Seven global Phase 3 trials with registrational potential are currently ongoing, evaluating pumitamig plus chemotherapy compared to standard of care treatments, in first-line small cell lung cancer (ROSETTA Lung-01, NCT06712355); first-line non-small cell lung cancer (ROSETTA Lung-02, NCT06712316); unresectable stage III non-small cell lung cancer (ROSETTA Lung-201, NCT07361497); first-line advanced PD-L1 ≥ 50% non-small cell lung cancer (ROSETTA Lung-202, NCT07361510); first-line triple-negative breast cancer (ROSETTA Breast-01, NCT07173751); first-line microsatellite stable colorectal cancer (ROSETTA CRC-203, NCT07221357); and first-line gastric cancer (ROSETTA Gastric-204, NCT07221149). Pumitamig is also being explored in 10+ novel-novel combination trials with ADCs and other novel modalities, with the aim of expanding its role across tumor types and identifying additional pivotal opportunities.

About BioNTech
BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody-drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

BioNTech Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s collaboration with Bristol Myers Squibb (BMS); BioNTech’s collaboration with Gilead; BioNTech and BMS’s ability to successfully co-develop and co-commercialize pumitamig (also known as BNT327 or BMS986545), if approved; the rate and degree of market acceptance of pumitamig, if approved; the initiation, timing, progress, and results of BioNTech’s research and development programs, including BioNTech’s current and future clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations, including expectations regarding the potential indications in which pumitamig may be approved, if at all; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; and discussions with regulatory agencies. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the impact of tariffs and escalations in trade policy; competition related to BioNTech’s product candidates; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech’s product candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market its product candidates, if approved; BioNTech’s ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

CONTACTS

BioNTech
Media Relations
Jasmina Alatovic
Media@biontech.de

Investor Relations
Douglas Maffei, PhD
Investors@biontech.de

1 American Cancer Society. Triple-Negative Breast Cancer. https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html. Accessed October 15, 2026.

COLUMBUS, Ohio, Oct. 22, 2026 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, today announced that its Board of Directors declared quarterly dividends on its preferred stock and an increased quarterly dividend on its common stock for the fourth quarter of 2026.

On the Company’s 8.625% Non-Cumulative Perpetual Preferred Stock, Series A (NYSE: BFH-PrA), the Board of Directors declared a quarterly cash dividend of $21.56 per share (equivalent to $0.539 per depositary share, each representing a 1/40th interest in a share of preferred stock). The dividend is payable on December 15, 2026 to preferred stockholders of record at the close of business on November 30, 2026.

On the Company’s 8.875% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (NYSE: BFH-PrB), the Board of Directors declared a quarterly cash dividend of $22.19 per share (equivalent to $0.55475 per depositary share, each representing a 1/40th interest in a share of preferred stock). The dividend is payable on December 15, 2026 to preferred stockholders of record at the close of business on November 30, 2026.

On the Company’s common stock, the Board of Directors declared a quarterly cash dividend of $0.25 per share, a 9% increase from the prior quarterly dividend of $0.23 per share, payable on December 15, 2026 to common stockholders of record at the close of business on November 30, 2026.

About Bread Financial^®
Bread Financial^® (NYSE: BFH) is a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions to millions of U.S. consumers. Our payment solutions deliver growth for some of the most recognized brands in travel & entertainment, specialty apparel, health & beauty, jewelry, sporting goods, technology and electronics, as well as home & furniture through our co-brand and private label credit cards and pay-over-time products providing choice and value to our shared customers. Additionally, we offer Bread Financial general purpose credit cards and saving products that empower our customers and their passions for a better life.​

Bread Financial proudly marks 30 years of success in 2026. To learn more about our global associates, our performance and our sustainability progress, visit breadfinancial.com or follow us on Instagram and LinkedIn.

Contacts
Brian Vereb – Investor Relations
Brian.Vereb@BreadFinancial.com

Susan Haugen – Investor Relations
Susan.Haugen@BreadFinancial.com

Rachel Stultz – Media
Rachel.Stultz@BreadFinancial.com

COSTA MESA, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today announced that it plans to release the Company’s 2026 third quarter financial results on November 5, 2026, prior to the stock market opening. Stephen G. Oswald, the Company’s chairman, president and chief executive officer, and Suman Mookerji, the Company’s senior vice president and chief financial officer, will host a call that day at 10:00 a.m. PT (1:00 p.m. ET) to review these results.

To access the conference call, please pre-register using this registration link. Registrants will receive a confirmation with dial-in details. Mr. Oswald and Mr. Mookerji will speak on behalf of the Company and anticipate the meeting and Q&A period to last approximately 45 minutes. A live webcast of the event can be accessed using this link. A replay of the webcast will be available on the Ducommun website at www.ducommun.com.

About Ducommun Incorporated

Ducommun Incorporated delivers value-added innovative products, aftermarket and manufacturing solutions to customers in the aerospace, defense and space markets and aspires to contribute to the advancement of those industries. Founded in 1849, the Company specializes in two core areas — Electronic Systems and Structural Systems — to produce complex products and components for commercial aircraft platforms and mission-critical military and space programs. For more information, visit Ducommun.com.

CONTACTS:

Suman Mookerji, Senior Vice President, Chief Financial Officer, 657.335.3665

ATLANTA, Oct. 22, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its third quarter results before the market open on Thursday, November 12, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day.

The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13762373. The replay will be available until November 19, 2026.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://ir.aveanna.com/. The online replay will be available for one week following the call.

About Aveanna Healthcare

Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 39 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit www.aveanna.com.

CONTACT: Investor Contact

Matt Buckhalter
Chief Financial Officer
Ir@aveanna.com

Built on data, analytics, specialized knowledge and AI-powered capabilities, Brown & Brown COMPASS helps customers and teammates make more informed decisions.

DAYTONA BEACH, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) — Brown & Brown, Inc. (NYSE: BRO) (“the Company”) today introduced COMPASS, a connected intelligence ecosystem that brings together the Company’s data, analytics, specialized knowledge and AI-enabled capabilities to help customers better understand risk and make more informed insurance decisions.

Built specifically to enhance insurance strategy and portfolio optimization, Brown & Brown COMPASS brings together proprietary data, advanced analytics, specialized knowledge, and AI-powered capabilities. While many AI solutions in the market adapt a general-purpose model to a single workflow, COMPASS was built around the data, decisions and experience that drive the insurance business.

“Insurance organizations have access to more data and technology than ever before, but the industry’s greatest opportunity is to connect those capabilities around the decisions customers and insurance professionals make every day,” said Steve Hearn, president of Brown & Brown Retail. “COMPASS brings together capabilities that have traditionally operated separately, giving our teams a more complete view of a customer’s risks and opportunities and helping turn fragmented information into relevant insight. That broader context can support more informed recommendations, better decisions and stronger outcomes across the insurance value chain.”

The impact is already evident. In Employee Benefits, customers using Brown & Brown’s Health Plan Intelligence (HPI) capabilities have experienced an average five-year cost trend of less than 4%, compared with an industry and market norm of approximately 7% to 9%.

In Property & Casualty, COMPASS analytics helped a Fortune 50 company evaluate whether its insurance purchasing philosophy aligned with its appetite for hazard risk. The analysis informed a significant restructuring of the company’s insurance program, reducing premium spending by 65% while also substantially reducing potential risk volatility.

Brown & Brown COMPASS will also support digital quoting and servicing experiences that simplify how Personal Lines customers evaluate and manage coverage. For ultra-high-net-worth and single-family-office customers, it will deliver institutional-grade analytics to maximize buying power, evaluate risk transfer and optimize portfolios, capabilities rarely available in Personal Lines.

“One of our greatest strengths is the knowledge we’ve built across Brown & Brown over many years,” said Powell Brown, president and chief executive officer. “COMPASS helps connect that knowledge in new ways, making it easier for our teammates to turn insights into action for our customers. When we help our customers make more informed decisions, everybody wins.”

COMPASS builds on the Company’s broader investment in data, analytics and AI, including the creation of its Digital Innovation and Insights Group and collaborations with Anthropic, McKinsey and Accenture.

“The innovation behind COMPASS is not one technology or tool, but the way we are bringing together Brown & Brown’s data, analytics, specialized knowledge and AI-enabled capabilities in a connected ecosystem,” said Arun Narayanan, chief innovation officer at Brown & Brown. “By building around the real-world decisions our teammates and customers make, we can develop solutions that are both practical and scalable, accelerate how insight is applied across our business and continually expand what COMPASS can deliver.”

By the end of 2026, the Company expects COMPASS-powered knowledge assistants and business intelligence solutions to be available to thousands of teammates, beginning in the U.S. and expanding to additional markets over time. An expanded suite of customer solutions across Property & Casualty, Employee Benefits and Personal Lines is planned for early 2027.

To learn more about COMPASS, visit https://us.bbrown.com/compass.

About Brown & Brown, Inc.
Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

This press release may contain certain forward-looking statements relating to future results. These statements are not historical facts but instead represent only Brown & Brown’s current belief regarding future events, many of which, by their nature, are inherently uncertain and outside of Brown & Brown’s control. It is possible that Brown & Brown’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning Brown & Brown and its business, including factors that potentially could materially affect Brown & Brown’s financial results and condition, as well as its other achievements, is contained in Brown & Brown’s filings with the Securities and Exchange Commission. All forward-looking statements made herein are made only as of the date of this release, and Brown & Brown does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which Brown & Brown hereafter becomes aware.

For more information:
Jenny Goco
Vice President of Public Relations & Communications
(386) 333-6066
jenny.goco@bbrown.com

To Nasdaq Copenhagen

 22 October 2026

FIXING OF COUPON RATES       

Fixing of coupon rates effective from 26 October 2026

Effective from 26 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 26 October 2026 to 25 January 2027:

Uncapped bonds
DK0030522818, (SNP), maturity in 2027, new rate as at 26 October 2026: 3.2770% pa

Effective from 26 October 2026, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted.

Bonds with quarterly interest rate fixing
The new coupon rates will apply from 26 October 2026 to 26 January 2027:

Uncapped bonds
DK0030513585, (Tier2), maturity in 2032, new rate as at 26 October 2026: 6.4900% pa

Questions may be directed to Investor Relations at investor_relations@nykredit.dk or Press Officer Peter Klaaborg, tel +45 44 55 14 94.

Attachment

• Fixing of coupon rates – Nykredit Realkredit – 20261022

Decision allows for uninterrupted manufacturing activities as T1 Energy continues construction on solar cell fab in Texas

AUSTIN, Texas and NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) — T1 Energy Inc. (NYSE: TE) (“T1,” “T1 Energy,” or the “Company”) announced it has received a waiver from the Department of Commerce that supports our advanced photovoltaic module manufacturing activities and plans to expand U.S. solar cell manufacturing. T1, the largest American-owned manufacturer of silicon-based TOPCon solar modules, requested the expedited waiver to import up to 1.725GW of solar cells to facilitate uninterrupted manufacturing at T1’s G1_Dallas solar module facility in order to meet existing and expected contracted demand.

The waiver relates to the Trump Administration’s Section 232 proclamation in August that takes decisive steps to prevent market dumping and price manipulation of imported polysilicon and solar products derived from polysilicon. T1 unequivocally supports the proclamation and believes the Commerce Department’s action strengthens American manufacturing and provides a foundation for a thriving domestic solar industry. T1 requested the waiver to ensure access to necessary solar cells for a limited duration while construction on the 2.1 GW Phase 1 of the Company’s G2_Austin solar cell fab in Rockdale, Texas continues. T1 expects to produce the first solar cells at G2 in the first quarter of 2027.

“We appreciate the Commerce Department’s support in granting this waiver, allowing us to deliver solar modules assembled in Texas and expand U.S. solar cell manufacturing capacity without any unnecessary delays,” said Dan Barcelo, Chairman and CEO of T1 Energy. “Since the Section 232 proclamation, customer demand for domestic solar cells and modules has meaningfully risen, and receiving a waiver positions T1 to meet this demand.”

About T1 Energy

T1 Energy Inc. (NYSE: TE) is an energy solutions provider building an integrated U.S. supply chain for solar. In December 2024, T1 completed a transformative transaction, positioning the Company as one of the leading solar manufacturing companies in the U.S., with a complementary solar and storage strategy. Based in the U.S. with plans to expand its operations in America, the Company is also exploring value optimization opportunities across its portfolio of assets in Europe.

To learn more about T1, please visit www.T1energy.com and follow on social media.

Investor contact:

Jeffrey Spittel
EVP, Investor Relations and Corporate Development
jeffrey.spittel@T1energy.com
Tel: +1 409 599 5706

Media contact:

Russell Gold
EVP, Strategic Communications
russell.gold@T1energy.com
Tel: +1 214 616 9715

Cautionary Statement Concerning Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements with respect to the expected benefits of the waiver from the Department of Commerce and statements with respect to the expected timing for production of the first solar cells at G_2 Austin. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results, or achievements to be materially different from T1’s expectations and projections expressed or implied by the forward-looking statements. Important factors include, but are not limited to, those discussed under the caption “Risk Factors” in T1’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2026, as amended and supplemented by Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, and in T1’s other filings with the SEC, including risks related to: (1) T1’s ability to (i) construct and equip manufacturing facilities in a timely and cost-effective manner; (ii) target and retain customers and suppliers; (iii) attract and retain key employees and qualified personnel; (iv) protect its intellectual property; (v) comply with legal and environmental regulations; (vi) compete in international markets in light of export and import controls; (vii) incur substantially more debt; (viii) remediate the material weakness in T1’s internal control over financial reporting or otherwise maintain effective internal control over financial reporting; and (ix) qualify for the advanced manufacturing production credit under Section 45X of the Internal Revenue Code of 1986, as amended; (2) T1’s ability to secure a comprehensive financing solution to fund the remaining capital expenditure for G2_Austin Phase 1 on favorable terms, or at all, and the timing of such financing; (3) the concentration of T1’s operations in Texas and its dependence on a limited number of suppliers; (4) changes adversely affecting the flow of components and materials from international vendors, the costs of raw materials, components, equipment, and machinery; (5) general economic and geopolitical conditions; (6) changes in applicable laws or regulations, including environmental, export control and tax laws and incentives and renewable energy targets, as well as international trade policies, including tariffs, on T1’s products and competitive position; (7) the outcome of any legal proceedings relating to T1’s products and services, including intellectual property or product liability claims, commercial or contractual disputes, warranty claims, and other proceedings; and (8) the capital-intensive nature of T1’s business and its ability to raise additional capital on attractive terms or service its debt. The above referenced filings are available on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date of this press release and are based on information available to T1 as of the date of this press release, and T1 assumes no obligation to update such forward-looking statements, all of which are expressly qualified by the statements in this section, whether as a result of new information, future events or otherwise, except as required by law. T1 intends to use its website as a channel of distribution to disclose information which may be of interest or material to investors and to communicate with investors and the public. Such disclosures will be included on T1’s website in the ‘Investor Relations’ section. T1, and its CEO and Chairman of the Board, Daniel Barcelo, also intend to use certain social media channels, including, but not limited to, X, LinkedIn and Instagram, as means of communicating with the public and investors about T1, its progress, products, and other matters. While not all the information that T1 or Daniel Barcelo post to their respective digital platforms may be deemed to be of a material nature, some information may be. As a result, T1 encourages investors and others interested to review the information that it and Daniel Barcelo posts and to monitor such portions of T1’s website and social media channels on a regular basis, in addition to following T1’s press releases, SEC filings, and public conference calls and webcasts. The contents of T1’s website and its and Daniel Barcelo’s social media channels shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) — KBR (NYSE: KBR) announced today it has been awarded contracts to support the revamp of two ammonia plants owned and operated by AGF Nitrogen through its affiliated companies SKWP in Germany and LAT Nitrogen in Linz, Austria.

Utilizing KBR’s industry-leading ammonia technology and proven revamp capabilities, the upgrades will allow AGF Nitrogen to reduce natural gas consumption, improve energy efficiency, and lower CO₂ emissions in two of its key assets. Furthermore, the revamps will enable AGF Nitrogen to achieve its sustainability objectives while continuing to support food security for Europe. Responding to the evolving energy challenges in the European fertilizer production market, AGF Nitrogen has chosen to collaborate with KBR to deliver on these objectives.

Under the terms of the contracts, KBR will provide technology licensing, proprietary engineering design, post-BED services, process equipment and catalyst supply for the revamp of LAT Nitrogen’s 550 MTPD ammonia plant #2 in Linz, Austria. For SKWP’s 1,900 MTPD ammonia plant #2 in Lutherstadt Wittenberg, Germany, KBR will provide technology licensing, post-BED services, process equipment and catalyst supply, back-end modifications and a new ammonia converter for the synthesis loop, building on the proprietary engineering work awarded to KBR in March 2026.

KBR will also modernize the existing steam reforming sections at both plants, bringing them to the highest industry performance standards through the integration of KBR’s proprietary KBR Reforming Exchange System (KRES) technology. Upon completion, both plants are expected to be among the most energy-efficient ammonia production facilities in their technology segment.

“We are proud to build on our long-standing relationship with AGF Nitrogen and support the continued modernization of its ammonia assets,” said Jay Ibrahim, President, KBR Sustainable Technology Solutions. “These awards demonstrate how KBR’s deep ammonia expertise and differentiated technologies can help customers improve the efficiency and performance of existing plants while reducing their carbon footprint. By combining proven ammonia technology with our energy transition capabilities, we are helping customers operate more efficiently while creating long-term value from existing assets.”

KBR has decades of experience in ammonia technology, spanning new plants, modernization and complex revamps, with its technology deployed in more than 260 ammonia plants worldwide. We deliver tailored revamp and physics-enabled AI solutions that help customers improve the efficiency, reliability and sustainability of existing ammonia plants while reducing emissions and maximizing long-term asset value.

About KBR
KBR is a global, capital-light lifecycle solutions company serving customers in high-complexity industrial, energy and infrastructure markets. Through its advisory, technical, engineering and operating expertise, KBR helps customers shape investments, reduce risk, deploy complex technologies, improve performance and deliver reliable outcomes across the asset lifecycle.

Following the planned separation of the Mission Technology Solutions business, KBR will operate as a focused standalone company with differentiated customer relationships, global execution capabilities and a capital-efficient business model. The company is positioned to benefit from long-term secular growth trends across energy security, energy transition, industrial modernization, and infrastructure investment. KBR’s 15,000 employees operate across more than 40 countries.

About Trinzic
KBR’s Mission Technology Solutions business is expected to be spun off as an independent public company in January 2027 and will then operate under the new name Trinzic. The name is inspired by the word intrinsic, reflecting the essential capabilities, deep expertise, speed and trusted performance that have defined the business for decades. Trinzic will enter the market as a global company and partner to customers supporting some of the highest priority missions across national security, human performance, global operations and space. Trinzic will launch with more than $5 billion in annual revenue, established partnerships and contracts, 18,000 employees and a global footprint.

About AGF Nitrogen
AGF Nitrogen brings together the AGROFERT Group’s nitrogen businesses across Europe, including leading producers, suppliers and distributors of ammonia, fertilizers and related products. A wholly owned subsidiary of AGROFERT, a.s., AGF Nitrogen comprises LAT Nitrogen group of companies, Lovochemie, a.s., Duslo, a.s., SKW Stickstoffwerke Piesteritz GmbH, and GreenChem Holding B.V.

As Europe’s second-largest fertilizer producer, AGF Nitrogen provides essential products and services that support agriculture, food production, healthcare, transport, energy and defense. AGF Nitrogen’s annual production capacity is over 7 million tons of fertilizer and more than 3.5 million tons ammonia. Annual turnover is EUR 2.3 billion. AGF Nitrogen employs more than 5,400 people across Europe. Through its commitment to safety, reliability and operational excellence, the company helps meet the needs of more than 15,000 customers worldwide.

Forward Looking Statements

The statements in this press release that are not historical statements, including statements regarding KBR’s ammonia technology and revamp services are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks, uncertainties and assumptions, many of which are beyond the company’s control, that could cause actual results to differ materially from the results expressed or implied by the statements. These risks, uncertainties and assumptions include, but are not limited to, those set forth in the company’s most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks and other U.S. Securities and Exchange Commission filings, which discuss some of the important risks, uncertainties and assumptions that the company has identified that may affect its business, results of operations and financial condition. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

For further information, please contact:

Investors
Rachael Goldwait
Vice President, Investor Relations
713-753-5082
Investors@kbr.com

Media
Philip Ivy
Vice President, Global Communications and Marketing
713-753-3800
MediaRelations@kbr.com

Harvia Plc press release 22 October 2026 at 1:00 p.m. EEST

Harvia will publish its Interim report for the period of January−September 2026 on Thursday, 29 October 2026 at around 09:00 a.m. Finnish time. The stock exchange release and the presentation material will be available after publishing at https://harviagroup.com/reports-and-presentations/.

Harvia will hold a webcast for analysts, investors and media on 29 October 2026 at 11:00 a.m. EET. The conference will be held in English. Harvia’s CEO Matias Järnefelt and CFO Ari Vesterinen will host the event. The webcast can be followed at https://harvia.events.inderes.com/q3-2026.

A recording of the webcast will be available after the event on the company’s website https://harviagroup.com/reports-and-presentations/.

HARVIA PLC

For further information, please contact:
CFO Ari Vesterinen, ari.vesterinen@harvia.com, tel. +358 40 5050 440

Harvia is one of the leading companies operating in the sauna market globally, as measured by revenue. Harvia’s brands and product portfolio are well known in the market, and the company’s comprehensive product portfolio strives to meet the needs of the international sauna market of both private and professional customers.

Harvia’s revenue totaled EUR 198.9 million in 2025. Harvia Group employs over 700 professionals in Finland, United States, Germany, Romania, China and Hong Kong, Austria, Italy, Estonia, and Sweden. The company is headquartered in Muurame, Finland, adjacent to its largest sauna and sauna component manufacturing facility.

Read more: https://harviagroup.com